137 related articles for article (PubMed ID: 34750233)
1.
Currie GM; Trifunovic M; Liu J; Kim S; Gurney H
J Nucl Med Technol; 2022 Sep; 50(3):282-285. PubMed ID: 34750233
[TBL] [Abstract][Full Text] [Related]
2. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
[TBL] [Abstract][Full Text] [Related]
3. Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted
Meyer AR; Carducci MA; Denmeade SR; Markowski MC; Pomper MG; Pierorazio PM; Allaf ME; Rowe SP; Gorin MA
Ann Nucl Med; 2019 Aug; 33(8):617-623. PubMed ID: 31147927
[TBL] [Abstract][Full Text] [Related]
4. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.
Rowe SP; Gorin MA; Hammers HJ; Som Javadi M; Hawasli H; Szabo Z; Cho SY; Pomper MG; Allaf ME
Ann Nucl Med; 2015 Dec; 29(10):877-82. PubMed ID: 26286635
[TBL] [Abstract][Full Text] [Related]
5. Potential role of
Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
[TBL] [Abstract][Full Text] [Related]
6. PSMA-Based [(18)F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer.
Rowe SP; Macura KJ; Mena E; Blackford AL; Nadal R; Antonarakis ES; Eisenberger M; Carducci M; Fan H; Dannals RF; Chen Y; Mease RC; Szabo Z; Pomper MG; Cho SY
Mol Imaging Biol; 2016 Jun; 18(3):411-9. PubMed ID: 27080322
[TBL] [Abstract][Full Text] [Related]
7. Role of PSMA-targeted PET-CT in renal cell carcinoma: a systematic review and meta-analysis.
Singhal T; Singh P; Parida GK; Agrawal K
Ann Nucl Med; 2024 Mar; 38(3):176-187. PubMed ID: 38340144
[TBL] [Abstract][Full Text] [Related]
8. Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.
Urso L; Castello A; Rocca GC; Lancia F; Panareo S; Cittanti C; Uccelli L; Florimonte L; Castellani M; Ippolito C; Frassoldati A; Bartolomei M
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1299-1311. PubMed ID: 35217902
[TBL] [Abstract][Full Text] [Related]
9. Non-prostate cancer tumours: incidence on
Perry E; Talwar A; Sharma S; O'Connor D; Wong LM; Taubman K; Sutherland TR
Eur J Nucl Med Mol Imaging; 2022 Jul; 49(9):3277-3288. PubMed ID: 35254481
[TBL] [Abstract][Full Text] [Related]
10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
11. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted
Werner RA; Sheikhbahaei S; Jones KM; Javadi MS; Solnes LB; Ross AE; Allaf ME; Pienta KJ; Lapa C; Buck AK; Higuchi T; Pomper MG; Gorin MA; Rowe SP
Ann Nucl Med; 2017 Nov; 31(9):696-702. PubMed ID: 28831739
[TBL] [Abstract][Full Text] [Related]
12.
Parghane RV; Basu S
J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
[TBL] [Abstract][Full Text] [Related]
13. The Role of Radiolabeled Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for the Evaluation of Renal Cancer.
Evangelista L; Basso U; Maruzzo M; Novara G
Eur Urol Focus; 2020 Jan; 6(1):146-150. PubMed ID: 30120074
[TBL] [Abstract][Full Text] [Related]
14. Characterization of tumor thrombus in renal cell carcinoma with prostate specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT).
Tariq A; McGeorge S; Pearce A; Rhee H; Wood S; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Roberts MJ
Urol Oncol; 2022 Jun; 40(6):276.e1-276.e9. PubMed ID: 35466037
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of Prostate-Specific Membrane Antigen Positron Emission Tomography (PET) on intensification or deintensification of advanced renal cell carcinoma management.
Pathmanathan S; Tariq A; Pearce A; Rhee H; Kyle S; Raveenthiran S; Wong D; McBean R; Marsh P; Goodman S; Dhiantravan N; Esler R; Dunglison N; Navaratnam A; Yaxley J; Thomas P; Pattison DA; Goh JC; Gan CL; Roberts MJ
Eur J Nucl Med Mol Imaging; 2023 Dec; 51(1):295-303. PubMed ID: 37592084
[TBL] [Abstract][Full Text] [Related]
16. Prospective Comparison of PET Imaging with PSMA-Targeted
Rowe SP; Li X; Trock BJ; Werner RA; Frey S; DiGianvittorio M; Bleiler JK; Reyes DK; Abdallah R; Pienta KJ; Gorin MA; Pomper MG
J Nucl Med; 2020 Feb; 61(2):183-188. PubMed ID: 31451492
[TBL] [Abstract][Full Text] [Related]
17. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
[TBL] [Abstract][Full Text] [Related]
18. Comparison of 18F-DCFPyL and 18F-FDG PET/computed tomography for the restaging of clear cell renal cell carcinoma: preliminary results of 15 patients.
Liu Y; Wang G; Yu H; Wu Y; Lin M; Gao J; Xu B
Nucl Med Commun; 2020 Dec; 41(12):1299-1305. PubMed ID: 32941403
[TBL] [Abstract][Full Text] [Related]
19. Intraindividual Comparison of
Giesel FL; Will L; Lawal I; Lengana T; Kratochwil C; Vorster M; Neels O; Reyneke F; Haberkon U; Kopka K; Sathekge M
J Nucl Med; 2018 Jul; 59(7):1076-1080. PubMed ID: 29269569
[TBL] [Abstract][Full Text] [Related]
20. Incidental Detection of Thyroid Metastases From Renal Cell Carcinoma Using 68Ga-PSMA PET/CT to Assess Prostate Cancer Recurrence.
Zacho HD; Nielsen JB; Dettmann K; Haberkorn U; Petersen LJ
Clin Nucl Med; 2017 Mar; 42(3):221-222. PubMed ID: 28033223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
